Quest Management Inc (OTCMKTS:QSMG) stock had a nice day yesterday moving higher by 15% adding some needed liquidity. The driver for this move came from a Letter of Intent to acquire immunotherapy Biotech company Stemvax, Inc., from Dr. Dwain Morris-Irvin PhD. Upon Closing, Dr. Morris-Irvin will simultaneously become CEO of the newly formed Biotech division of Quest.
Los Angeles based Stemvax, Inc., founded in 2014 and doing business as StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. Stemvax focuses its efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer. Stemvax simultaneously focuses research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells.
Quest Management Inc (OTCMKTS:QSMG) by all accounts has added some top-level talent. Dr. Morris-Irvin received his PhD from UCLA School of Medicine, MPH, from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.
His PhD is in Pharmacology and Developmental Neuroscience with an emphasis on neural stem cell fate and differentiation. His research focused on neural development and Notch Signaling in mammalian neural stem cells. He also worked as an NIH/NINDS Post-Doctoral Fellow in Dr. Anders Bjorklund laboratory in Lund, Sweden. There, his focus was on research projects that investigated the potential role of cell replacement therapy for patients with Parkinson’s disease. They developed several protocols for the efficient generation of dopaminergic neurons from forebrain and ventral midbrain stem and progenitor cells.
Subscribe below and we’ll keep you on top of what’s happening before QSMG stock makes its next move.
Additionally, Dr. Morris-Irvin worked as a Research Scientist, Assistant Professor, and Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery. He led research investigations in the role of adaptive immunity in Parkinson’s disease. He also developed two patents in the area of immunotherapy for brain tumor patients, specifically Glioblastoma Multiforme (GBM). His research team focused on molecular mechanisms that impart therapeutic resistance in cancer cells, including cancer stem cells. They utilized this data to develop novel immunotherapies for brain tumor patients.
Quest Management believes that the Stemvax acquisition, and integration of Dr. Morris-Irvin into the Quest family will give Quest an immediate presence in a Biotech field that is not only working, but tremendously appreciated by those whose life it impacts. Dr. Morris-Irvin and his team are a foundation for many opportunities Quest will have, that will provide Quest the potential to be a significant stalwart in global Biotechnology pursuits.
The company announced recently the signing of a Stock Purchase Agreement between Quest Management’s President, Mr. Dmitrij Ozolins and TN3 LLC, a Wyoming limited liability company, whereby TN3 agreed to acquire 46,045,000 shares of common stock owned by Mr. Ozolins, which represents all of the shares owned by Mr. Ozolins.
The parties expect to close the acquisition on or about April 15, 2017. At the time of closing, Mr. Dan Martin, the CEO and controlling shareholder of TN3, will be appointed as a member of the Board of Directors of Quest. Mr. Martin, thereafter, intends to cause TN3 to vend into Quest, TN3’s assets, subsidiaries and divisions in equity swap transactions.
Mr. Martin is an accomplished C-level executive with success driving results across a broad base of middle-market companies in direct sales, technology, distribution, product development, and others. He has been an entrepreneur, corporate officer, and consultant. Starting his career in the 1990s while obtaining a BSBA in Finance from John Carroll University, he was co-founder of an Internet company which over the next five years achieved a 4% national market share in its niche. Since then, he has been actively involved in mergers and acquisitions, and bringing new products and services to new markets globally. His primary expertise, is understanding the needs of growing organizations, evaluating and defining the strategic objectives of a business, and communicating with stakeholders to successfully execute company objectives.
QSMG stock seems to be at the beginning of a move. Based on the technical pattern, I see it is worth watching these shares trade through this week, and get a few more clues. For more news on QSMG stock and other fast-moving penny stocks, please subscribe to OracleDispatch.com below.